Page last updated: 2024-12-08

nesosteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	158613
CHEMBL ID	2107446
SCHEMBL ID	1525263
MeSH ID	M0141924

Synonyms (19)

Synonym
nesosoteinum
2-(1,3-thiazolidine-3-carbonyl)benzoic acid
unii-445j9k442z
nesosteine
nesosteinum [latin]
nesosteine [inn]
nesosteina
84233-61-4
2-(3-thiazolidinylcarbonyl)benzoesaeure
445j9k442z ,
nesosteinum
o-(3-thiazolidinylcarbonyl)benzoic acid
nesosteina [spanish]
CHEMBL2107446
nesosteine [mart.]
DTXSID60233155
SCHEMBL1525263
Q27258704
AKOS040753252

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" The therapy was performed for 15 days, at the dosage of one vial given intramuscularly twice daily for the first seven days and then of one tablet orally thrice daily for the remaining eight days."	( Clinical trial with CO-1177: a preliminary report. Mbuyamba, P, 1986)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.96 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (37.50%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (62.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	1.96	1	0	N-acyl-amino acid
thiazoles [no description available]	5.66	7	3	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	1.96	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
vinblastine sobrerol: RN given is for parent cpd; structure	1.96	1	0	p-menthane monoterpenoid

Condition	Relationship Strength	Studies	Trials
Anaphylactic Reaction [description not available]	1.97	1	0
Bronchospasm [description not available]	1.97	1	0
Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.	1.97	1	0
Bronchial Spasm Spasmodic contraction of the smooth muscle of the bronchi.	1.97	1	0
Obstructive Lung Diseases [description not available]	3.36	1	1
Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.	3.36	1	1
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	4.32	2	2

chemdatabank.com